Trial Profile
Cohort study of Patients with metastatic colorectal cancer Treated by XELOX with bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 31 Jan 2013 New trial record